CRISPR Therapeutics AG (CRSP) Total Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has reported Total Current Liabilities for 12 years, with the latest figure at $136.3 million in Q1 2026.

• Quarterly Total Current Liabilities rose 14.1% year-over-year to $136.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.3 million (up 14.1% YoY) and the FY2025 annual result came in at $149.1 million, up 69.88% from the prior year.
• Total Current Liabilities fell to $136.3 million in Q1 2026 per CRSP's latest filing, from $149.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $150.9 million in Q3 2022 and troughed at $87.8 million in Q4 2024.
• A 5-year average of $121.1 million and a median of $119.4 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities declined 26.27% in 2023, then soared 69.88% in 2025.
• Over 5 years, Total Current Liabilities stood at $121.1 million in 2022, then fell by 10.17% to $108.8 million in 2023, then slipped by 19.31% to $87.8 million in 2024, then jumped by 69.88% to $149.1 million in 2025, then decreased by 8.61% to $136.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $136.3 million, $149.1 million, and $119.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.